ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of EGFR and ALK , with an IC 50 of 1.08 nM for EGFR and an IC 50 of 2.395 nM for ALK . ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR , ALK , and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis ( Apoptosis ). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > BRK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Mitochondrial Metabolism | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.